KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-cash Items (2018 - 2020)

Historic Non-cash Items for Esperion Therapeutics (ESPR) over the last 3 years, with Q2 2020 value amounting to $72.4 million.

  • Esperion Therapeutics' Non-cash Items fell 713.46% to $72.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $72.4 million, marking a year-over-year decrease of 713.46%. This contributed to the annual value of $109.1 million for FY2019, which is 3064.58% up from last year.
  • As of Q2 2020, Esperion Therapeutics' Non-cash Items stood at $72.4 million, which was down 713.46% from $3.2 million recorded in Q1 2020.
  • In the past 5 years, Esperion Therapeutics' Non-cash Items registered a high of $109.1 million during Q4 2019, and its lowest value of $2.3 million during Q1 2018.
  • For the 3-year period, Esperion Therapeutics' Non-cash Items averaged around $46.2 million, with its median value being $54.4 million (2019).
  • In the last 5 years, Esperion Therapeutics' Non-cash Items skyrocketed by 293771.84% in 2019 and then crashed by 9500.36% in 2020.
  • Over the past 3 years, Esperion Therapeutics' Non-cash Items (Quarter) stood at $83.5 million in 2018, then skyrocketed by 30.65% to $109.1 million in 2019, then crashed by 33.61% to $72.4 million in 2020.
  • Its Non-cash Items was $72.4 million in Q2 2020, compared to $3.2 million in Q1 2020 and $109.1 million in Q4 2019.